Results 1 to 2 of 2

Thread: Pfizer breast cancer drug

  1. #1

    Default Pfizer breast cancer drug

    Approved Pfizer breast cancer drug impresses in latest study

    (Reuters) - Pfizer Inc said on Wednesday the first formal late-stage trial of its approved treatment for advanced breast cancer, Ibrance, was stopped early after the medicine met its goal of delaying progression of the disease in previously treated patients.

    J.P.Morgan analyst Chris Schott said in a research note that the successful trial results should boost demand for the recently approved treatment, which works differently than approved medicines and has blockbuster sales potential. Some analysts have predicted the drug could eventually generate annual sales of more than $5 billion.
    Pfizer breast cancer drug attachment.php?attachmentid=151&stc=1&d=1429902302

    Pfizer said the Phase 3 study, called Paloma 3, was halted after an independent data monitoring board determined that Ibrance, also known as palbociclib, had proven its effectiveness among patients with advanced disease who had previously been treated with anti-estrogen drugs. Data from the study will be presented at an upcoming medical meeting, the largest U.S. drugmaker said.
    Patients taking Ibrance in combination with AstraZeneca Plc's Faslodex (fulvestrant), a widely used treatment to block estrogen, were deemed to have fared better in terms of disease progression than those taking Faslodex alone.
    The trial enrolled patients whose breast cancer was classified as estrogen-receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-).
    Ibrance was approved by the U.S. Food and Drug Administration in February for such patients, but only ones who had not previously been treated for advanced disease.
    The accelerated approval was based on results of a study that showed Ibrance delayed progression of disease significantly longer than Novartis AG's Femara (letrozole), a member of another class of breast cancer treatments called aromatase inhibitors.
    Pfizer is conducting a large trial called Paloma-2, which it hopes will confirm the benefits of Ibrance as a first-line treatment, in combination with Femara.
    Ibrance works by blocking two enzymes, cyclin-dependent kinase 4 and 6, that are involved in cell growth.
    A number of other drugmakers, including Eli Lilly and Co , are testing drugs that block the same or similar enzymes, as potential treatments for various cancers.
    Pfizer shares were up 0.9 percent at $35.34 in afternoon trading on the New York Stock Exchange.

    (Additional reporting by Vidya L Nathan in Bengaluru; editing by Matthew Lewis)

    Attached Images  

  2. Similar Threads

    1. Replies: 1
      Last Post: 08-08-2018, 06:49 PM
    2. Breast Cancer
      By Medical Videos in forum Ob/Gyn
      Replies: 1
      Last Post: 06-15-2018, 04:36 PM
    3. Breast cancer improved survival after ovary removal
      By Medical Videos in forum Breast Cancer
      Replies: 1
      Last Post: 12-21-2015, 06:44 AM
    4. Replies: 0
      Last Post: 07-28-2007, 05:43 PM
    5. Replies: 0
      Last Post: 04-27-2007, 08:15 AM
  3. #2
    Junior Member
    Join Date
    Jun 2018
    Virgin Islands


    Virgin Islands

    Default Pfizer breast cancer drug

    Hi Mazzer, my late partner died of breast cancer. I understand where you are...

    We can help with growing help, tutorials about making oil or just, being there, if you need us, but and however harsh this may sound - but its got to be said we can not help you with supply.

    One thing that you may wish to also look into is Mistletoe...

Tags for this Thread



Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
About us
Medical Educational Site for Medical Students and Doctors Contains Free Medical Videos ,Atlases,Books,Drug Index ,Researches ,Health and Medical Technology news.
  • Privacy Policy
  • Join us
    Powered by vBulletin® Version 4.2.0 Copyright © 2015
  • vBulletin®
  • Solutions, Inc. All rights reserved. vBulletin Metro Theme by
  • PixelGoose Studio